01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu

Help protect your youngest patients against critical IPD-causing serotypes1

VAXNEUVANCE elicited superior immune responses vs PCV13 for shared Serotype 3 and unique Serotypes 22F and 33F through the first year of life and beyond*

In 2010, PCV13 introduced routine pediatric coverage against Serotype 3.2,3 According to a pooled analysis from 2018-2021, Serotypes 3, 22F, and 33F were three of the top six IPD-causing serotypes in children under 5 years.1,a,b

Additionally, Serotypes 3, 22F, and 33F can cause significant IPD-related morbidity in children and are associated with varying degrees of antimicrobial resistance.4-6

VAXNEUVANCE is administered as a 4-dose series given at 2, 4, 6, and 12 through 15 months of age.

*Randomized controlled trials assessing the clinical efficacy of VAXNEUVANCE compared to PCV13 have not been conducted.

In a pooled analysis from 2018-2021, ~1 in 4 cases of IPD in children under 5 years of age were caused by the following serotypes1,a,b:

Image Showing the Percentage of IPD Cases in Children under 5 Years of Age Caused by Serotypes 3 (~8%), 22F (~7%), and 33F (~9%).Image Showing the Percentage of IPD Cases in Children under 5 Years of Age Caused by Serotypes 3 (~8%), 22F (~7%), and 33F (~9%).

aFrom 2018-2021, the top 6 IPD-causing serotypes in children under 5 years were 15C, 33F, 19F, 3, 23B, and 22F.
Serotypes 15C and 23B are not included in any pediatric PCV in the US.1,3,7,8

bThe CDC noted that historic decreases of IPD burden in 2020 were likely due to the associated mitigation measures implemented during the COVID-19 pandemic, as documented by the Active Bacterial Core (ABC) surveillance data.9

VAXNEUVANCE provided superior immune responses for shared Serotype 3 vs PCV13 postdose 3 and 4*

Superior IgG response rate for shared Serotype 3 vs PCV13

Postdose 3 (primary series)

93.1% VAXNEUVANCE; 74% PCV1393.1% VAXNEUVANCE; 74% PCV13

IgG response rate percentage point difference (VAXNEUVANCE-PCV13), 19.1 (95% CI: 14.4, 24.0).

Superior IgG GMC Ratios for shared Serotype 3 vs PCV13

Postdose 3 (primary series)

70% Higher Immunogenicity vs PCV13

lgG GMC Ratio vs PCV13, 1.70
(95% CI: 1.54, 1.86).

Superior IgG GMC Ratios for shared Serotype 3 vs PCV13

Postdose 4 (booster dose)

43% Higher Immunogenicity vs PCV1343% Higher Immunogenicity vs PCV13

lgG GMC Ratio (VAXNEUVANCE/PCV13),
1.43 (95% CI: 1.30, 1.57).

*Randomized controlled trials assessing the clinical efficacy of VAXNEUVANCE compared to PCV13 have not been conducted.

default-sum-open-background-color
default-sum-close-background-color
false
default-sum-open-hover-color
default-sum-open-focus-color
default-sum-close-focus-color
.default-sum-close-hover-color

Study design

Study 8 was a pivotal, double-blind, active comparator-controlled study in which participants were randomized to receive VAXNEUVANCE (N=860) or PCV13 (N=860) in a 4-dose series. The first 3 doses were administered to infants at 2, 4, and 6 months of age and the fourth dose was administered to children at 12 through 15 months of age. Participants also received other licensed pediatric vaccines concomitantly. Immune responses were measured by IgG response rates, IgG GMCs, and OPA GMTs for all 15 serotypes contained in VAXNEUVANCE.

Review CDC, AAP, and AAFP recommendations

Review CDC, AAP, and AAFP recommendations

Learn about storage & handling information

Learn about storage & handling information

View safety & tolerability data

View safety & tolerability data

Discover resources for your practice and patients

Discover resources for your practice and patients

AAP, American Academy of Pediatrics; AAFP, American Academy of Family Physicians; CDC, Centers for Disease Control and Prevention; CI, confidence interval; GMC, geometric mean concentration (mcg/mL); GMT, geometric mean titer; IgG, Immunoglobulin G; IPD, invasive pneumococcal disease; OPA, opsonophagocytic activity; PCV, pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.

References

  1. Centers for Disease Control and Prevention (CDC). Visualization – Based on 1998-2022 serotype data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance (ABCs). Updated July 22, 2024. Accessed September 27, 2024. https://data.cdc.gov/d/qvzb-qs6p/visualization
  2. Gierke R, Wodi P, Kobayashi M. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 17: Pneumococcal disease. Centers for Disease Control and Prevention. Last reviewed May 1, 2024. Accessed August 1, 2024. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html?CDC_AAref_Val=https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html
  3. Prevnar 13. Prescribing Information. Pfizer, Inc.; 2019.
  4. Hu T, Weiss T, Owusu-Edusei K, Petigara T. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States. J Med Econ. 2020;23(12):1653-1660. doi:10.1080/13696998.2020.1840216
  5. Varghese J, Chochua S, Tran T, et al. Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017. Clin Microbiol Infect. 2020;26(4):512.e1-512.e10. doi:10.1016/j.cmi.2019.09.008
  6. Azarian T, Mitchell PK, Georgieva M, et al. Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. PLoS Pathog. 2018;14(11):e1007438. doi:10.1371/journal.ppat.1007438
  7. Prevnar 20. Prescribing Information. Pfizer, Inc.; 2023.
  8. Pneumococcal vaccination. Centers for Disease Control and Prevention. Last reviewed September 12, 2024. Accessed September 26, 2024. https://www.cdc.gov/pneumococcal/vaccines/index.html
  9. Centers for Disease Control and Prevention. 2020 Data and Impacts of COVID-19. Last reviewed May 22, 2024. Accessed June 26, 2024. cdc.gov/abcs/reports/2020-data.html? CDC_AAref_Val=https://www.cdc.gov/abcs/reports-findings/data-2020.html
ExternalSitePopup

By clicking on this link, you will be leaving Merck Vaccines.

Cancel
Proceed
Cancel
Proceed

Indications and Usage

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

 

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

 

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

 

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

 

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

 

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications and Usage

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

 

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

 

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

 

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

 

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

 

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.